Welcome to our dedicated page for Fosun Internatio news (Ticker: FOSUY), a resource for investors and traders seeking the latest updates and insights on Fosun Internatio stock.
News about Fosun International Limited (FOSUY) covers a broad range of topics reflecting its activities as a global innovation-driven consumer group. Company announcements and media releases describe developments across pharmaceuticals and healthcare, cultural tourism and consumption, financial services, and insurance, as well as updates on its innovation and globalization strategy.
Investors and observers can find news on Fosun’s pharmaceutical and healthcare initiatives, including progress in innovative drugs, medical devices, and healthcare services under entities such as Fosun Pharma and Henlius. Releases highlight clinical and regulatory milestones, new therapeutic indications, and the use of artificial intelligence in areas such as drug development decision-making and clinical trial prediction.
Coverage also includes cultural tourism and consumption news, such as performance and expansion of Club Med resorts under Fosun Tourism Group, cultural events, and consumer-focused projects. In financial services and insurance, news items discuss developments at Fosun Insurance Portugal (Fidelidade), asset servicing activities in Europe, and strategic portfolio adjustments, including asset sales and retained businesses.
Another important theme in Fosun-related news is ESG and sustainability. Articles describe its ESG ratings, inclusion in sustainability indices and yearbooks, climate disclosure practices, and social responsibility programs such as the Rural Doctors Program and contributions to global malaria treatment. Governance and award recognitions, including honors from organizations like Corporate Governance Asia, also feature prominently.
For those following FOSUY, this news stream provides insight into how Fosun advances its stated strategy of "Innovation + Globalization", how its core subsidiaries perform, and how it integrates ESG considerations into its operations. Regularly reviewing these updates can help readers understand the group’s evolving business focus and corporate priorities.
Fosun International (OTC:FOSUF) reported 2025 revenue of RMB173.43 billion and adjusted industrial operation profit of RMB4 billion. Adjusted NAV was RMB133.5 billion (NAV per share HKD18.1). The Group booked a RMB23.4 billion non-cash impairment, largely real estate-related.
Core units generated RMB128.2 billion (74% of revenue); Fosun Pharma net profit rose 21.69% to RMB3.371 billion. Management announced a share buyback, asset disposals, a USD205 million bond tender, and targets to exceed RMB10 billion net profit and cut interest-bearing debt below RMB60 billion.
Fosun International (OTC:FOSUF) reported 2025 results and management commentary on March 31, 2026. Adjusted NAV totaled RMB133.5 billion, with a NAV per share of HKD18.1. Group revenue was RMB173.43 billion and adjusted industrial operation profit was RMB4.0 billion.
The company booked a non-cash book loss of RMB23.4 billion from impairments (≈55% real estate, ≈45% non-core goodwill/intangibles). Management announced a share buyback program, insiders and the major shareholder will increase holdings, and said it will focus resources on core, high-growth businesses.
Fosun International (OTC:FOSUF) reported total 2025 revenue of RMB173.43 billion and adjusted industrial operation profit of RMB4 billion. Overseas revenue was RMB94.86 billion (54.7%). The Group recorded a RMB23.4 billion book loss from impairments and revaluations.
Fosun invested RMB7.8 billion in technology innovation, secured multiple drug approvals and clinical starts, held RMB61.1 billion cash, and set medium-term targets including restoring annual profit to ~RMB10 billion.
Fosun (OTC:FOSUF) reported 2025 operating revenue of RMB173.4 billion and a loss attributable to owners of the parent of RMB23.4 billion, driven mainly by non-cash impairment provisions on certain historical projects and goodwill.
The Group said core businesses remain stable: four core enterprises generated RMB128.2 billion (74% of revenue), overseas revenue was 54.7%, operating cash flow stayed positive, and credit ratings remained stable.
Fosun International (OTC: FOSUF) announced its MSCI ESG rating was upgraded from AA to AAA on March 26, 2026, the Group's highest rating since 2021. The upgrade reflects strengthened ESG governance, climate commitments (peak by 2028, carbon neutrality by 2050), and sustainability disclosures aligned with TCFD and IFRS S2.
Fosun cited achievements across responsible investment, business ethics, clean-technology opportunities, Henlius approvals, and wide recognition from S&P Global and FTSE Russell.
Fosun International (OTC:FOSUF) received the Certificate of Excellence in Environmental, Social and Governance Reporting from the Hong Kong Management Association on 23 February 2026, recognizing its ESG strategy, disclosure and governance.
The group highlighted its "Create IMPACT" sustainability strategy, a USD990 million three-year sustainability-linked syndicated loan (Sept 2025), climate targets (peak by 2028; neutrality by 2050) and rising ESG scores including FTSE4Good inclusion and an FTSE Russell score of 4.2.
Fosun International (OTC: FOSUF) reported an improved FTSE Russell ESG score of 4.2 and was included in the FTSE4Good Index Series for the fifth consecutive time on January 21, 2026. The company outperformed industry and China corporate averages across governance, environment, and social dimensions.
Fosun achieved full scores of 5.0 in Environmental Supply Chain, Anti-Corruption, Risk Management, Social Supply Chain, Corporate Governance, and overall Governance; multiple other categories scored ≥4.0. It also maintained MSCI AA, HSI ESG AA-, and a top 1% placement in S&P Global Sustainability Yearbook 2025 (China).
Fosun International (OTC: FOSUF) was awarded TVB's highest ESG accolade, the "Outstanding ESG Award", plus "Best in ESG Practices" and "Best in ESG Report" on 19 December 2025. TVB cited Fosun's global operations across healthcare, tourism, consumption and insurance and its ESG performance over the past year.
Key disclosed developments include a Pfizer licensing agreement for oral GLP-1R agonists, inclusion of multiple Fosun Pharma products and CAR-T Yi Kai Da on the 2025 national medical insurance and inaugural commercial insurance innovative drug lists, and approvals/marketing of HANSIZHUANG in nearly 40 countries.
Fosun International (OTC:FOSUF) was named an "ESG Leading Enterprise" at the 7th Bloomberg Businessweek/Chinese Edition ESG awards on 19 November 2025, recognizing ESG strategy, governance, disclosure and stakeholder engagement.
Key disclosed credentials include an MSCI ESG rating of AA, inclusion in the S&P Global Sustainability Yearbook 2025 (top 1% China), an HSI sustainability rating AA-, Hang Seng Corporate Sustainability Benchmark inclusion, and continued FTSE4Good membership.
Fosun highlighted healthcare innovations (anti‑PD‑1 HANSIZHUANG approved in nearly 40 jurisdictions; biopharma reach to nearly 60 countries and >850,000 patients), climate targets (peak by 2028, neutrality by 2050), and social programs reaching 78 counties and supporting 25,000 rural doctors.
Fosun International (OTC:FOSUF) was awarded the Gold Award and Best Sustainability Team at The Asset Corporate Sustainability Leadership Awards 2025 on 6 November 2025 in Singapore.
The company cited multiple ESG recognitions: an MSCI ESG rating of AA, inclusion in the S&P Global Sustainability Yearbook 2025 (top 1% China), an HSI sustainability rating of AA-, continued inclusion in the Hang Seng Corporate Sustainability Benchmark, and constituent status in FTSE4Good. Fosun highlighted global healthcare reach, citing nearly 60 countries served and specific product approvals (HANQUYOU in 50+ markets; HANSIZHUANG in nearly 40 markets).
Fosun reaffirmed a carbon pledge to peak emissions by 2028 and achieve carbon neutrality by 2050 and described board-level ESG governance structures.